Table 2 Selected Hematological Responses to Supplementation.
Placebo (n = 10) | Cinnulin (n = 12) | P-value (GxT) | Reference Interval | |
|---|---|---|---|---|
BUN:Creatinine | 0.21 | 8–27 | ||
Pre | 16 ± 5 | 16 ± 4 | ||
Mid | 19 ± 5 | 18 ± 4 | ||
Post | 16 ± 4 | 18 ± 4 | ||
Bilirubin (mg/dL) | 0.50 | 0.1–1.2 | ||
Pre | 0.5 ± 0.1 | 0.7 ± 0.3 | ||
Mid | 0.5 ± 0.1 | 0.8 ± 0.4 | ||
Post | 0.5 ± 0.2 | 0.6 ± 0.3 | ||
Alkaline Phosphatase (IU/L) | 0.12 | 25–150 | ||
Pre | 77 ± 17 | 65 ± 14 | ||
Mid | 71 ± 16 | 67 ± 16 | ||
Post | 67 ± 16 | 60 ± 11 | ||
Aspartate aminotransferase (IU/L) | 0.94 | 0–40 | ||
Pre | 29 ± 15 | 29 ± 17 | ||
Mid | 26 ± 11 | 26 ± 13 | ||
Post | 25 ± 8 | 24 ± 8 | ||
Alanine aminotransferase (IU/L) | 0.59 | 0–40 | ||
Pre | 30 ± 16 | 38 ± 28 | ||
Mid | 30 ± 17 | 34 ± 25 | ||
Post | 28 ± 14 | 32 ± 22 | ||
Cholesterol (mg/dL) | 0.81 | 100–199 | ||
Pre | 192 ± 49 | 185 ± 44 | ||
Mid | 191 ± 50 | 190 ± 36 | ||
Post | 193 ± 47 | 190 ± 33 | ||
Triacylglycerol (mg/dL) | 0.75 | 0–149 | ||
Pre | 165 ± 107 | 166 ± 142 | ||
Mid | 172 ± 111 | 152 ± 76 | ||
Post | 195 ± 146 | 162 ± 132 | ||
HDL (mg/dL) | 0.73 | 40–59 | ||
Pre | 55 ± 14 | 50 ± 13 | ||
Mid | 54 ± 15 | 48 ± 13 | ||
Post | 55 ± 16 | 50 ± 13 | ||
VLDL (mg/dL) | 0.31 | 5–40 | ||
Pre | 33 ± 21 | 25 ± 9 | ||
Mid | 34 ± 21 | 30 ± 15 | ||
Post | 36 ± 22 | 25 ± 11 | ||
LDL (mg/dL) | 0.44 | 0–99 | ||
Pre | 105 ± 52 | 107 ± 36 | ||
Mid | 102 ± 57 | 112 ± 34 | ||
Post | 99 ± 54 | 111 ± 29 |